Acetylcholinesterase inhibitory potencies of new pyrazoline derivatives

Abstract

Alzheimer's disease (AD) has no current cure and its mechanism is not fully known, but treatments for symptoms are available. Acetylcholinesterase (AChE) has been reported to be an applicable therapeutic target in patient with AD. Acetylcholinesterase inhibitors (AChEIs) are commonly used for it. For this purpose, novel series of pyrazoline based compounds [2-(3-(4-methoxyphenyl)-5-aryl-4,5-dihydro-1H-pyrazol-1-yl)benzo[d]thiazole, 1-9] were synthesized and AChE inhibitory potencies were reported here. The results indicated that compound 1 (Ki= 0.13±0.004 μM) possessed the highest AChE inhibitory effect in series, which is two times more potent than the reference compound Tacrin (Ki= 0.26±0.045 μM). So, pyrazoline derivative 1 can be considered as a lead inhibitor in designing new AChE inhibitors

Keywords

• : Acetylcholinesterase
• alzheimer disease
• benzothiazol
• pyrazoline

References

1. [1] Ragab HM, Teleb M, Haidar HR, Gouda N. Chlorinated tacrine analogs: design, synthesis and biological evaluation of their anti-cholinesterase activity as potential treatment for Alzheimer's disease. Bioorg Chem. 2019; 86: 557-568. [CrossRef]
2. [2] Kumar B, Dwivedi AR, Sarkar B, Gupta SK, Krishnamurthy S, Mantha AK, Parkash J, Kumar V. 4,6- Diphenylpyrimidine derivatives as dual inhibitors of monoamine oxidase and acetylcholinesterase for the treatment of Alzheimer's disease. Acs Chem Neurosci. 2019; 10(1): 252-265. [CrossRef]
3. [3] Carmo Carreiras M, Ismaili L, Marco-Contelles J. Propargylamine-derived multi-target directed ligands for Alzheimer's disease therapy. Bioorg Med Chem Lett. 2020; 30(3): 126880. [CrossRef]
4. [4] Zhou A, Hu JP, Wang LR, Zhong GC, Pan J, Wu ZY, Hui A. Combined 3D-QSAR, molecular docking, and molecular dynamics study of tacrine derivatives as potential acetylcholinesterase (AChE) inhibitors of Alzheimer's disease. J Mol Model. 2015; 21(10): 277. [CrossRef]
5. [5] Carter MD, Simms GA, Weaver DF. The development of new therapeutics for Alzheimer's disease. Clin Pharmacol Ther. 2010; 88(4): 475-486. [CrossRef]
6. [6] Sasikala R, Thirumurthy K, Mayavel P, Thirunarayanan G. Eco-friendly synthesis and antimicrobial activities of some 1-phenyl-3(5-bromothiophen-2-yl)-5-(substituted phenyl)-2-pyrazolines. Org Med Chem Lett. 2012; 2(1): 20. [CrossRef]
7. [7] Chen L, Duan H, Zhang X, Zhang Q, Huang H, Zhao J, Chen B, Hua C, Gou X. Design, synthesis, and biological evaluation of novel 1,3,4‐ thiadiazolylpyrazolines compounds containing ferrocene. J Heterocyclic Chem. 2018; 55, 1978. [CrossRef]
8. [8] Kumar G, Tanwar O, Kumar J, Akhter M, Sharma S, Pillai CR, Alam MM, Zaman MS. Pyrazole-pyrazoline as promising novel antimalarial agents: a mechanistic study. Eur J Med Chem. 2018; 149: 139-147. [CrossRef]

9. [9] Eid NM, George RF. Facile synthesis of some pyrazoline-based compounds with promising anti-inflammatory activity. Future Med Chem. 2018; 10(2): 183-199. [CrossRef]
10. [10] Gokhan-Kelekci N, Yabanoglu S, Kupeli E, Salgin Goksen U, Ozgen O, Ucar G, Yesilada E, Kendi E, Yesilada A, Bilgin AA. A new therapeutic approach in Alzheimer disease: some novel pyrazole derivatives as dual MAO-B inhibitors and antiinflammatory analgesics. Bioorg Med Chem. 2007; 15(17): 5775-5786. [CrossRef]
11. [11] Shah MS, Khan SU, Ejaz SA, Afridi S, Rizvi SUF, Najam-Ul-Haq M, Iqbal J. Cholinesterases inhibition and molecular modeling studies of piperidyl-thienyl and 2-pyrazoline derivatives of chalcones. Biochem Biophys Res Commun. 2017; 482(4): 615-624. [CrossRef]
12. [12] Ucar G, Gokhan N, Yesilada A, Bilgin AA. 1-N-Substituted thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: a novel cholinesterase and selective monoamine oxidase B inhibitors for the treatment of Parkinson's and Alzheimer's diseases. Neurosci Lett. 2005; 382(3): 327-331. [CrossRef]
13. [13] Can OD, Ozkay UD, Kaplancikli ZA, Ozturk Y. Effects of some 1,3,5-trisubstitued-2-pyrazoline derivatives on depression and anxiety parameters of mice. Arch Pharm Res. 2009; 32(9): 1293-1299. [CrossRef]
14. [14] Ozdemir A, Altintop MD, Kaplancikli ZA, Can OD, Ozkay UD, Turan-Zitouni G. Synthesis and evaluation of new 1,5-diaryl-3-[4-(methyl-sulfonyl)phenyl]-4,5-dihydro-1H-pyrazole derivatives as potential antidepressant agents. Molecules. 2015; 20(2): 2668-2684. [CrossRef]
15. [15] Gomha SM, Abdallah MA, Abbas IM, Kazem MSH. Synthesis, cytotoxicity evaluation, molecular docking and utility of novel chalcones as precursors for heterocycles incorporating pyrazole moiety. Med Chem. 2018; 14(4): 344- 355.
16. [16] Gul HI, Yamali C, Sakagami H, Angeli A, Leitans J, Kazaks A, Tars K, Ozgun DO, Supuran CT. New anticancer drug candidates sulfonamides as selective hCA IX or hCA XII inhibitors. Bioorg Chem. 2018; 77: 411-419. [CrossRef]
17. [17] Chimenti F, Bolasco A, Manna F, Secci D, Chimenti P, Granese A, Befani O, Turini P, Cirilli R, La Torre F, Alcaro S, Ortuso F, Langer T. Synthesis, biological evaluation and 3D-QSAR of 1,3,5-trisubstituted-4,5-dihydro-(1H)-pyrazole derivatives as potent and highly selective monoamine oxidase a inhibitors. Curr Med Chem. 2006; 13(12): 1411- 1428.
18. [18] Jagrat M, Behera J, Yabanoglu S, Ercan A, Ucar G, Sinha BN, Sankaran V, Basu A, Jayaprakash V. Pyrazoline based MAO inhibitors: synthesis, biological evaluation and SAR studies. Bioorg Med Chem Lett. 2011; 21(14): 4296–4300. [CrossRef]
19. [19] Ozgun DO, Gul HI, Yamali C, Sakagami H, Gulcin I, Sukuroglu M, Supuran CT. Synthesis and bioactivities of pyrazoline benzensulfonamides as carbonic anhydrase and acetylcholinesterase inhibitors with low cytotoxicity. Bioorg Chem. 2019; 84: 511-517. [CrossRef]
20. [20] Yamali C, Gul HI, Ece A, Taslimi P, Gulcin I. Synthesis, molecular modeling, and biological evaluation of 4-[5-aryl3-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl] benzenesulfonamides toward acetylcholinesterase, carbonic anhydrase I and II enzymes. Chem Biol Drug Des. 2018; 91(4): 854-866. [CrossRef]
21. [21] Gul HI, Tugrak M, Sakagami H, Taslimi P, Gulcin I, Supuran CT. Synthesis and bioactivity studies on new 4-(3-(4- substitutedphenyl)-3a,4-dihydro-3H-indeno[1,2-c]pyrazol-2-yl) benzenesulfonamides. J Enzyme Inhib Med Chem. 2016; 31(6): 1619-1624. [CrossRef]
22. [22] Kucukbay H, Durmaz B. Antifungal activity of organic and organometallic derivatives of benzimidazole and benzothiazole. Arzneimittelforsch. 1997; 47(5): 667-670.
23. [23] Kalina PH, Shetlar DJ, Lewis RA, Kullerstrand LJ, Brubaker RF. 6-Amino-2-benzothiazole-sulfonamide. The effect of a topical carbonic anhydrase inhibitor on aqueous humor formation in the normal human eye. Ophthalmol. 1988; 95(6): 772-777. [CrossRef]
24. [24] Mohr E, Nair NP, Sampson M, Murtha S, Belanger G, Pappas B, Mendis T. Treatment of Alzheimer's disease with sabeluzole: functional and structural correlates. Clin Neuropharmacol. 1997; 20(4): 338-345.
25. [25] Kagaya T, Kajiwara A, Nagato S, Akasaka K, Kubota A. E2011 a novel, selective and reversible inhibitor of monoamine oxidase type A. J Pharmacol Exp Ther. 1996; 278(1): 243-251.
26. [26] Aboelmagd A, Ali IAI, Salem EMS, Abdel-Razik M. Synthesis and antifungal activity of some smercaptotriazolobenzothiazolyl amino acid derivatives. Eur J Med Chem. 2013; 60: 503-511. [CrossRef]
27. [27] Gul HI, Tugrak M, Gul M, Mazlumoglu S, Sakagami H, Gulcin I, Supuran CT. New phenolic mannich bases with piperazines and their bioactivities. Bioorg Chem. 2019; 90: 103057. [CrossRef]
28. [28] Gul HI, Tugrak M, Gul M, Sakagami H, Umemura N, Anil B. Synthesis and cytotoxicities of new azafluorenones with apoptotic mechanism of action and cell cycle analysis. Anticancer Agents Med Chem. 2018; 18(12): 1770-1778.
29. [29] Tugrak M, Gul HI, Bandow K, Sakagami H, Gulcin I, Ozkay Y, Supuran CT. Synthesis and biological evaluation of some new mono mannich bases with piperazines as possible anticancer agents and carbonic anhydrase inhibitors. Bioorg Chem. 2019; 90: 103095. [CrossRef]
30. [30] Tugrak M, Gul HI, Sakagami H, Gulcin I, Supuran CT. New azafluorenones with cytotoxic and carbonic anhydrase inhibitory properties: 2-aryl-4-(4-hydroxyphenyl)-5H-indeno[1,2-b]pyridin-5-ones. Bioorg Chem. 2018; 81: 433-439. [CrossRef]
31. [31] Tugrak M, Yamali C, Sakagami H, Gul HI. Synthesis of mono mannich bases of 2-(4-hydroxybenzylidene)-2,3- dihydroinden-1-one and evaluation of their cytotoxicities. J Enzyme Inhib Med Chem. 2016; 31(5): 818-823. [CrossRef]
32. [32] Sharma V, Sharma KV. Synthesis and biological activity of some 3,5-diaryl-1-benzothiazolopyrazoline derivatives: reaction of chalcones with 2-hyrazinobenzothiazoles. E-J Chem. 2009; 6(2): 348-356. [CrossRef]
33. [33] El-Sayed NA, Farag AE, Ezzat MAF, Akincioglu H, Gulcin I, Abou-Seri SM. Design, synthesis, in vitro and in vivo evaluation of novel pyrrolizine-based compounds with potential activity as cholinesterase inhibitors and antiAlzheimer's agents. Bioorg Chem. 2019; 93: 103312. [CrossRef]